Generex inks deal with Sanofi-Aventis for insulin supply
Generex Biotechnology Corporation announced that it has signed a long-term agreement with Sanofi-Aventis Deutschland GmbH for the manufacture and supply of recombinant human insulin crystals for commercial and clinical trial use in Generex’s proprietary buccal insulin spray product, Generex Oral-lyn™. The financial terms of the arrangement were not disclosed.
The API (Active Pharmaceutical Ingredient) Supply agreement will provide the Company with a source of insulin for major regulatory markets including the United States and Canada and a number of other regions where the Company is pursuing regulatory approvals for Generex Oral-lyn™. The Company’s regulatory team will commence the process of updating any and all current submissions to include sanofi-aventis’ insulin crystal which will be formulated in the Generex Oral-lyn™ commercial product.
“We are very pleased to have entered into this long term supply agreement for insulin crystal”, said Anna Gluskin, Generex’s President and Chief Executive Officer. “It solidifies one of our key product components which will assist in the smooth transition into commercialization of our flagship product, Generex Oral-lyn™, into major markets where we will seek to establish a new paradigm for the treatment of diabetes.”
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
